14 Aug , 2025 By : Debdeep Gupta
The company posted a consolidated revenue from operations at Rs 540 crore, higher by 59 percent on year, and a net profit of Rs 135.8 crore, up 65 percent on year. Revenue from the CRDMO business grew up 70 percent on year. Anthem's EBITDA rose by 52.7 percent to Rs 214.3 crore.
Recently listed CRDMO player Anthem Biosciences are sharply higher by nearly 5 percent after the company posted strong June quarter results.
The company posted a consolidated revenue from operations at Rs 540 crore, higher by 59 percent on year, and a net profit of Rs 135.8 crore, up 65 percent on year. Revenue from the CRDMO business grew up 70 percent on year. Anthem's EBITDA rose by 52.7 percent to Rs 214.3 crore.
Ajay Bhardwaj, Chairman, Managing Director and CEO, Anthem Biosciences attributed to result to good performance across the CRDMO and Specialty Ingredients business. “Strong YoY growth in Q1FY26 reflects a CRDMO revenue stream that started ramping up since Q2FY25." the CRDMO business generated nearly 84 percent of the revenue during the June quarter.
Anthem Bio has completed the expansion of its 54 kL custom synthesis capacity at Unit II, Harohalli, and commenced commercial operations. At its Unit III, operations commenced in a phased manner, including the custom synthesis block with an R&D laboratory, pilot laboratory, kilo laboratory, and hydrogenation facility.
The Harohalli unit also saw the inauguration of a state-of-the-art commercial-scale peptide manufacturing facility with a 16 kL capacity and a hi-potent manufacturing facility with a 2.5 kL capacity. At Unit IV, Harohalli, construction is underway for a new greenfield facility on a 30-acre site, the management informed.
0 Comment